FeesSafety
Pluang+

Tortoise North American Pipeline ETF outperforms S&P 500 with stable midstream energy exposure.

Market News
17 Sep 2026
Seeking Alpha
View Source
Bullish
Tortoise North American Pipeline ETF outperforms S&P 500 with stable midstream energy exposure.

The Tortoise North American Pipeline ETF (TPYP) offers investors exposure to U.S. and Canadian midstream energy infrastructure, focusing on stable, fee-based returns rather than commodity price swings. Over five years, TPYP delivered a 20% total return, outperforming the S&P 500's 15%, while maintaining lower volatility compared to oil-linked ETFs. Factors such as geopolitical disruptions and rising U.S. LNG exports support strong demand for midstream assets. The fund's portfolio is primarily U.S.-listed and heavily weighted in natural gas pipelines, with a low expense ratio of 0.40%.

The Tortoise North American Pipeline ETF (TPYP) offers a stable approach to midstream energy investing. For readers following the energy sector, here is Pluang's market snapshot as of Sep 17, 2026 17:02 WIB: Of 30 priced Energy-sector US stocks tradable on Pluang, 21 rose and 7 fell today. Notable movers include UEC (Uranium Energy Corp) at USD 10.25 with a 1-day change of +1.69% and Pluang order activity of 95% Buy, CEG (Constellation Energy Corporation) at USD 263.75 with +1.63% and 89% Buy, and TTE (TotalEnergies SE) at USD 92.06 with +1.34% but 98% Sell order activity.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
47 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App